MicroRNA‑18b acts as an oncogene in gastric cancer by directly targeting Kruppel‑like factor 6

Luo, Dongming; Chen, Junqiang; Huang, Shifeng; Xu, Junyi; Song, Xuemin; Yu, Pengcheng

doi:10.3892/mmr.2019.9830

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KLF6 is initially considered as a tumor suppressor in prostate cancer, and is regulated through activating CDHL promoter (Tian et al 2020). Additionally, the above tumor suppressive function of KLF6 is further confirmed in hepatocellular carcinoma and gastric cancer, and is related to the effect of cell differentiation (He et al 2017;Luo et al 2019;Tian et al 2019). In this study, KLF6 was reduced in GCC cells, and was a target of miR-200c-3p confirmed by dual-luciferase reporter assay, which were consistent with the bioinformatic prediction.…”

Section: Discussionsupporting

confidence: 85%

MiR-200c-3p aggravates gastric cell carcinoma via KLF6

Wang

Lu²,

et al. 2021

Genes Genom

View full text Add to dashboard Cite

Background Gastric cell carcinoma (GCC) is a common and high-incidence malignant gastrointestinal cancer that seriously threatens human life and safety. Evidences suggest that microRNAs (miRNAs) exhibit an essential role in regulating the occurrence and development of GCC, while the effects and possible mechanisms remain to be further explored. Objective This study was designed to explore whether miR-200c-3p exerted its functional role in the growth and metastasis of GCC, and investigate the possible mechanisms. Methods The expression levels of miR-200c-3p in GCC tissues and cell lines were detected by qRT-PCR analysis. The functional role of miR-200c-3p in the viability, proliferation, migration and invasion of GCC cells were evaluated by CCK-8, EdU, wound healing and Transwell assays. In addition, the candidate targets of miR-200c-3p was predicted and confirmed by dual-luciferase reporter assay. Moreover, the relationship between miR-200c-3p and target (Krüppel like factor 6, KLF6) was assessed by qRT-PCR and western blot assays. Besides, the expression levels of KLF6 in GCC cells were determined by qRT-PCR and western blot assays. Furthermore, the role of KLF6 in the viability, proliferation, migration and invasion of GCC cells mediated with miR-200c-3p mimics was evaluated by CCK-8, EdU, wound healing and Transwell assays. Results In the present study, a new tumor promoting function of miR-200c-3p was disclosed in GCC. We found that the expression of miR-200c-3p was obviously increased in clinic GCC tissues and cell lines. In addition, down-regulation of miR-200c-3p suppressed cell viability, proliferation, migration, and invasion in GCC cells. Moreover, KLF6 was verified as a direct target of miR-200c-3p by binding its 3’-UTR. Additionally, KLF6 was remarkably decreased and was negatively associated with the miR-200c-3p expression in GCC cell lines. Furthermore, over-expression of KLF6 retarded the effects of miR-200c-3p on the growth and metastasis of GCC cell lines. Conclusions MiR-200c-3p potentially played a tumor-promoting role in the occurrence and development of GCC, which may be achieved by targeting KLF6. Graphic abstract

show abstract

Section: Discussionsupporting

confidence: 85%

MiR-200c-3p aggravates gastric cell carcinoma via KLF6

Wang

Lu²,

et al. 2021

Genes Genom

View full text Add to dashboard Cite

show abstract

“…The importance of miRNAs in prognosis, diagnosis, and treatment as well as drug resistance of GI cancer has been widely reported. [14][15][16][17] Recently, accumulating evidence has indicated that a variety of miRNAs could target CD molecules in GI cancers, thereby modulating the cancer progression. Using the Gene Expression Omnibus database and RNA-Seq colon cancer data from The Cancer Genome Atlas data portal, Gao et al 18 reported that CD92 was targeted by miR-183, miR-206, and miR-147 in colon cancer, and differentially expressed genes (DEGs) were identified between colon tumor samples and adjacent normal samples.…”

Section: Introductionmentioning

confidence: 99%

Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy

Zhang

Kaboli

et al. 2021

Int J Biol Markers

View full text Add to dashboard Cite

Background: Cluster of differentiation molecules are markers of immune cells that have been identified as a potential immunotherapeutic target for cancer treatment. MicroRNAs are small non-coding RNAs that act as tumor suppressors or oncogenes whose importance in diagnosis, prognosis, and treatment of gastric and colorectal cancers has been widely reported. However, their association with cluster of differentiation molecules in gastrointestinal cancers has not been well studied. Therefore, our study aimed to analyze the relationship between microRNAs and cluster of differentiation molecules in gastrointestinal cancers, and to identify cluster of differentiation molecule-associated microRNAs as prognostic biomarkers for gastrointestinal cancer patients. Methods: Targetscan, Starbase, DIANA microT, and miRDB were used to investigate microRNA profiles that might be correlated with cluster of differentiation molecules in gastrointestinal cancers. Moreover, The Cancer Genome Atlas data analysis was used to investigate the association between cluster of differentiation molecules and microRNA expression in patients with gastric, colon, rectal, pancreatic, and esophageal cancers. The Kaplan–Meier plotter was used to identify the association between overall survival and cluster of differentiation molecule-associated microRNA expression in gastrointestinal cancer patients. Results: miR-200a, miR-559, and miR-1236 were negatively associated with CD86, CD81, and CD160, respectively, in almost all types of gastrointestinal cancers, which were further verified in the in vitro studies by transfecting microRNA mimics in gastric cancer, colon cancer, pancreatic, and esophageal cell lines. Conclusion: Our study showed that miR-200a, miR-1236, and miR-559 are identified as cluster of differentiation-associated microRNAs in gastrointestinal cancers, providing a novel perspective to identify new therapeutic targets for cancer immunotherapy in gastrointestinal cancer patients.

show abstract

“…Accordingly, Cancer therapy may benefit greatly from the study of microRNAs. It's well-known that miRNAs are known to affect prognosis, diagnosis, therapy, and medication resistance of GI cancer [34][35][36][37][38][39]. We outlined the most recent research on miR-34a functions in GI cancers in this review.…”

Section: Cancer Cell Internationalmentioning

confidence: 99%

MicroRNA-34 and gastrointestinal cancers: a player with big functions

Gao,

Zhou,

Morshedi

2024

Cancer Cell Int

View full text Add to dashboard Cite

It is commonly assumed that gastrointestinal cancer is the most common form of cancer across the globe and is the leading contributor to cancer-related death. The intricate mechanisms underlying the growth of GI cancers have been identified. It is worth mentioning that both non-coding RNAs (ncRNAs) and certain types of RNA, such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), can have considerable impact on the development of gastrointestinal (GI) cancers. As a tumour suppressor, in the group of short non-coding regulatory RNAs is miR-34a. miR-34a silences multiple proto-oncogenes at the post-transcriptional stage by targeting them, which inhibits all physiologically relevant cell proliferation pathways. However, it has been discovered that deregulation of miR-34a plays important roles in the growth of tumors and the development of cancer, including invasion, metastasis, and the tumor-associated epithelial-mesenchymal transition (EMT). Further understanding of miR-34a’s molecular pathways in cancer is also necessary for the development of precise diagnoses and effective treatments. We outlined the most recent research on miR-34a functions in GI cancers in this review. Additionally, we emphasize the significance of exosomal miR-34 in gastrointestinal cancers.

show abstract

MicroRNA‑18b acts as an oncogene in gastric cancer by directly targeting Kruppel‑like factor 6

Abstract: Gastric cancer (GC) is the fourth most frequently occurring cancer and the second most common cause of cancer-associated mortality worldwide. An increasing number of studies have reported that microRNAs (miRNAs/miRs) contribute to the regulation of GC development and progression.

Cited by 5 publications

References 33 publications

MiR-200c-3p aggravates gastric cell carcinoma via KLF6

MiR-200c-3p aggravates gastric cell carcinoma via KLF6

Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy

MicroRNA-34 and gastrointestinal cancers: a player with big functions

Contact Info

Product

Resources

About